Focusing on the research and development of biological macromolecules of innovative research and development, Vonsun Pharmatech (Suzhou) Co., Ltd. (hereinafter referred to as Vonsun Tech) is an innovative core R&D enterprise of Wanbang Biopharmaceuticals (Group) (hereinafter referred to as Wanbang Biopharma), which is the core subsidiary of Fosun Pharma. It was jointly invested by Wanbang Biopharma and the team of entrepreneurial scientists, and is an innovative R&D enterprise for the development of bio-macromolecular drugs such as recombinant proteins, polysaccharides and nucleic acids. Vonsun Tech with the patent of entrepreneurial team of scientists, platform technology, suzhou talents and innovation resource, cultivated in biotech drugs research and development, especially in early drug discovery and development of the biotechnology products. It focuses on chronic diseases such as endocrine metabolism, cardiovascular, anti-tumor clinical unmet demand, creating an internationally competitive technology platform for biological macromolecular drug development. It continuously introduces innovative drugs with significant clinical and market value and became a globally competitive biotech drugs research and development company.